a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer
Industry Biotechnology
A.I.dvisor tells us that CLRB and SAGE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRB and SAGE's prices will move in lockstep.
Ticker / NAME | Correlation To CLRB | 1D Price Change % | ||
---|---|---|---|---|
CLRB | 100% | -2.73% | ||
SAGE - CLRB | 30% Poorly correlated | -6.17% | ||
XFOR - CLRB | 29% Poorly correlated | -5.80% | ||
PTGX - CLRB | 28% Poorly correlated | -3.45% | ||
ARDX - CLRB | 27% Poorly correlated | -8.90% | ||
NGNE - CLRB | 27% Poorly correlated | -12.29% | ||
More |
Ticker / NAME | Correlation To CLRB | 1D Price Change % |
---|---|---|
CLRB | 100% | -2.73% |
cancer theme (87 stocks) | 29% Poorly correlated | +0.89% |
treatment theme (61 stocks) | 29% Poorly correlated | +0.91% |
biopharmaceuticals theme (52 stocks) | 28% Poorly correlated | +2.00% |
biotechnology theme (248 stocks) | 28% Poorly correlated | +5.56% |
drugs theme (265 stocks) | 26% Poorly correlated | +5.37% |